Meeting
2023 ASCO Annual Meeting
Real-world outcomes of patients (pts) with malignant solid tumors treated with immune checkpoint inhibitors (ICI) in relation to smoking status: The SAKK 80/19 SMOKER study.
Authors
Tämer El Saadany
Division of Oncology/Hematology, Kantonsspital Graubuenden, Chur, Switzerland
Tämer El Saadany , Ulf Petrausch , Alfonso Rojas Mora , Thomas Winder , Christoph Renner , Magdalena Benda , Patrick Reimann , Patrizia Froesch , Andreas Jakob , Adriana Clavijo Daza , Gisela Müller , Roger Anton Fredy Von Moos , Michael Thomas Mark
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Health Services Research and Quality Improvement
Track
Quality Care/Health Services Research
Sub Track
Real-World Data/Outcomes
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 6619)
DOI
10.1200/JCO.2023.41.16_suppl.6619
Abstract #
6619
Poster Bd #
111
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Dual CDKN2A/MTAP loss compared to CDKN2A loss alone and response to immune-checkpoint inhibitors (ICI) in advanced solid tumors.
First Author: Elio Adib
Poster
2023 ASCO Annual Meeting
Multi-center real-world data curation and assessment of tumor growth rate and overall survival in advanced NSCLC treated with PD-(L)1 immune checkpoint inhibitor therapy.
First Author: Chiharu Sako
Poster
2023 ASCO Annual Meeting
Safety and efficacy of immune checkpoint inhibitors (ICIs) in patients (pts) with cardiac metastases (mets) from solid tumors.
First Author: Amin Nassar
Poster
2022 ASCO Annual Meeting
Predictors of response to immune checkpoint inhibitors (ICI) rechallenge post-disease progression in solid tumors: A systematic review and meta-analyses.
First Author: Hassan Mohammed Abushukair